Next Article in Journal
Coherent Feature Extraction with Swarm Intelligence Based Hybrid Adaboost Weighted ELM Classification for Snoring Sound Classification
Next Article in Special Issue
Disability and Patient-Reported Satisfaction in Women with Idiopathic Intracranial Hypertension: A Comparative Study of Venous Sinus Stenting and Medical Management
Previous Article in Journal
The Role of Endoscopic Ultrasound in Ampullary Lesion Management
Previous Article in Special Issue
Diagnostic Accuracy of Non-Contrast-Enhanced Time-Resolved MR Angiography to Assess Angioarchitectural Classification Features of Brain Arteriovenous Malformations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 14
Issue 17
10.3390/diagnostics14171856
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Post-Thrombectomy Subarachnoid Hemorrhage: Incidence, Predictors, Clinical Relevance, and Effect Modulators

by
Huanwen Chen
1,2,†,
Marco Colasurdo
3,†,
Mihir Khunte
4,5,
Ajay Malhotra
5 and
Dheeraj Gandhi
6,*
1
National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
2
Department of Neurology, MedStar Georgetown University Hospital, Washington, DC 20007, USA
3
Department of Interventional Radiology, Oregon Health & Science University, Portland, OR 97239, USA
4
Warren Alpert Medical School, Brown University, Providence, RI 02903, USA
5
Department of Radiology, Yale New Haven Hospital, New Haven, CT 06510, USA
6
Departments of Radiology, Neurosurgery, and Neurology, University of Maryland Medical Center, Baltimore, MD 21201, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Diagnostics 2024, 14(17), 1856; https://doi.org/10.3390/diagnostics14171856
Submission received: 1 August 2024 / Revised: 19 August 2024 / Accepted: 23 August 2024 / Published: 25 August 2024
(This article belongs to the Special Issue Advances in Cerebrovascular Imaging and Interventions)
Browse Figures
Versions Notes

Abstract

:
Background: Subarachnoid hemorrhage (SAH) following endovascular thrombectomy (EVT) is a poorly understood phenomenon, and whether it is associated with clinical detriment is unclear. Methods: This was an explorative analysis of a national database of real-world hospitalizations in the United States. Patients who underwent EVT were included. Patients were divided into SAH and non-SAH groups, and hospitalization outcomes were compared using multivariable logistic regression models. Regression models were also used to identify significant predictors for post-EVT SAH, and significant modulators of SAH’s association with hospitalization outcomes were also assessed. Results: A total of 99,219 EVT patients were identified; 6174 (6.2%) had SAH. Overall, SAH was independently associated with increased odds of in-hospital mortality (21.5% vs. 10.6%, adjusted OR 2.53 [95%CI 2.23–2.87], p < 0.001) and lower odds of routine discharge to home with self-care (18.2% vs. 28.0%, aOR 0.58 [95%CI 0.52–0.65], p < 0.001). Distal/medium vessel occlusion (DMVO), coagulopathy, angioplasty or stenting, concurrent intraparenchymal hemorrhage (IPH), and female sex were associated with higher odds of SAH. DMVO was associated with particularly heightened risk of death (31.8% vs. 7.9%, aOR 6.99 [95%CI 2.99 to 16.3], p < 0.001), which was an effect size significantly larger than other sites of vascular occlusion (interaction p > 0.05). Conclusion: SAH is an uncommon but likely clinically detrimental post-EVT complication. DMVO, coagulopathy, angioplasty or stenting, concurrent IPH, and female sex were independently associated with higher odds of post-EVT SAH. SAH associated with DMVO-EVT may be particularly harmful.

1. Introduction

Endovascular thrombectomy (EVT) is standard of care for select patients with acute ischemic stroke; however, it is not without risks [1,2]. Intracranial hemorrhage is a dreaded complication, and it has been shown to be independently associated with poor outcomes [3]. While hemorrhagic transformations of the infarct bed are well-studied with clearly defined diagnostic criteria, post-EVT SAH is a less understood phenomenon. Numerous efforts have been made to continue expanding EVT indications to patients with larger infarcts [4,5,6,7,8,9,10], baseline frailty or underlying medical or neurological comorbidities [11,12,13,14,15,16], presenting in later time windows [17,18,19], and having more distal occlusions [20,21,22,23,24,25,26,27,28,29,30]. Thus, a better understanding of how hemorrhagic complications impact patient outcomes is needed, particularly SAH.
For EVT patients, SAH can occur via various mechanisms, such as vessel wall perforation during endovascular device navigation and manipulation, endothelial irritation during clot retrieval, as well as subarachnoid extension of intraparenchymal blood due to hemorrhagic transformation of ischemic infarct [31]. The presence of SAH may irritate the cerebral cortex and intracranial vasculature, which could increase the risk of seizures, cerebral vasospasm, and delayed hydrocephalus in severe cases [32,33]. Thus, a better understanding of post-EVT SAH is important for optimizing risk–benefit assessments during pre- and intra-operative EVT decision making. Based on prior clinical trial data, post-EVT SAH occurs in approximately 5% of patients with large vessel occlusions, and increased risk has been observed with multiple-pass EVT and distal or medium vessel occlusions (DMVOs). To date, investigations on the impact of post-EVT SAH on clinical outcomes is have yielded mixed results, with some reports suggesting that SAH is an independent risk factor for poor outcomes [31,34], and others suggesting that SAHs may be clinically benign [35,36,37]. Importantly, the current literature is largely based on data from clinical trials and academic medical centers with high procedural volumes, which may not be reflective of routine clinical practice [38]. To date, there have been scarce real-world data on the incidence and clinical importance of post-EVT SAH.
In this explorative analysis of a nationwide database of hospitalizations across community hospitals in the United States, we sought to analyze real-world data on post-EVT SAH to identify its predictors, its impact on outcomes, and factors that modify its clinical relevance.

2. Methods

This was a retrospective cohort study of the 2016 to 2021 Nationwide Readmissions Database (NRD), a part of the Healthcare Cost and Utilization Project (HCUP). The NRD is an administrative database that provides stratified real-world discharge information in the United States from community hospitals across 38 states.
Adult patients with acute ischemic stroke who underwent EVT were included. Protocols for patient selection and EVT procedures were based on local institution and provider preferences. To ensure that included patients did not have chronic infarction as a premorbid diagnosis, we excluded patients with missing NIH stroke scale (NIHSS) information. Patients with missing discharge information were excluded.
The primary exposure of interest was SAH, and patients were divided into SAH and non-SAH groups. Patient demographics (age, sex), NIHSS, stroke location, and concomitant intravenous thrombolysis were captured. Stroke location was categorized into anterior versus posterior, as well as by vessel size—large (internal carotid, vertebral, or basilar artery), middle cerebral artery (MCA) tree, and DMVO (anterior and posterior cerebral arteries). The decision to combine all occlusions of the MCA tree into one group was due to limitations of the ICD-10 coding system, which does not allow specification of the MCA segment (M1, M2, M3, etc.). Stroke risk factors such as atrial fibrillation, hypertension, hyperlipidemia, diabetes, smoking history, and congestive heart failure were also extracted, as were anticoagulant use, antiplatelet use, underlying coagulopathy, and concurrent intraparenchymal hemorrhage (IPH). Elixhauser comorbidity index was calculated for each patient to estimate overall medical comorbidity burden [39].
The primary endpoints of this study were rates of in-hospital mortality and routine hospital discharge to home with self-care, which is a surrogate marker for excellent neurological outcomes [26,40]. Variables used for this study were identified using International Classification of Diseases, 10th edition (ICD-10) codes; all codes used for this study are listed in Supplementary Table S1.

Statistical Methods

The number of patients was calculated using discharge-level weights. Continuous data were expressed as mean ± SD and compared via Student’s t-test. Categorial data were represented as percentages and compared with Rao–Scott chi-square tests. Multivariable logistic regression models were used to identify significant predictors for SAH, including a list of variables identified a priori based on prior literature: age, sex, NIHSS, intravenous thrombolysis, concurrent IPH, stroke location, coagulopathy, stroke risk factors (atrial fibrillation/flutter, hypertension, hyperlipidemia, diabetes, congestive heart failure, smoking), antithrombotic medication use (antiplatelet or anticoagulant), and overall comorbidity burden as measured by Elixhauser comorbidity index [39]. Additional interaction analyses were performed to identify significant effect modulators of SAH’s association with discharge outcomes. p-values less than 0.05 were deemed statistically significant. All statistical analyses were performed using R, Version 3.6.2.

3. Results

3.1. Patient Characteristics

A total of 99,219 AIS patients who underwent endovascular thrombectomy with available NIH stroke scale information were identified; 6174 (6.2%) had SAH. Overall, SAH patients were more likely to be female and to have underlying coagulopathy. Furthermore, SAH patients were more likely to have undergone angioplasty or stenting procedures in addition to EVT, and they were more likely to have suffered concurrent intraparenchymal hemorrhage. Full details regarding patient characteristics are presented in Table 1 and Supplementary Table S2.

3.2. Impact of SAH on Patient Outcomes

SAH was significantly associated with increased rate and odds of in-hospital mortality (21.5% vs. 10.6%, adjusted OR 2.53 [95%CI 2.23–2.87], p < 0.001; Figure 1) as well as lower rate and odds of routine discharge (18.2% vs. 28.0%, adjusted OR 0.58 [95%CI 0.52–0.65], p < 0.001; Figure 1). In a sensitivity analyses, isolated SAH remained statistically significantly associated with lower odds of routine discharge (adjusted OR 0.64 [95%CI 0.57 to 0.73], p < 0.001) and higher odds of death (adjusted OR 2.11 [95%CI 1.83 to 2.44], p < 0.001)

3.3. Predictors of SAH Risk

In multivariable regression analysis, several factors were significantly associated with higher odds of SAH, including DMVO, coagulopathy, angioplasty or stenting, concurrent IPH, and female sex (Table 2). Long-term anticoagulant use and posterior circulation occlusion were significantly associated with lower risk of SAH (Table 2). In a sensitivity analysis of isolated SAH, female sex, MCA, DMVO, angioplasty/stenting, coagulopathy, and posterior circulation location remained statistically significantly associated with risk of isolated ICH (all p < 0.05).

3.4. Modulators of SAH’s Association with Poorer Outcomes

Various factors significantly modulated the association of SAH with poorer outcomes. In terms of in-hospital mortality, SAH for patients who underwent EVT in the DMVO location was associated with a particularly heightened risk of death (adjusted OR 6.99 [95%CI 2.99 to 16.3], p < 0.001; Figure 2), which was significantly elevated compared to MCA (interaction p = 0.003, Figure 2) and proximal LVO locations (interaction p = 0.014, Figure 2). Female sex was also significantly associated with an augmentation of increased mortality risk associated with SAH (interaction p = 0.009), though the absolute differences in rates of in-hospital death associated with SAH were similar for men and women (8.6% and 8.3%, respectively; Figure 2). Finally, older age (75 years or older) significantly augmented the reduced odds of routine discharge associated with SAH (interaction p = 0.018), though the absolute difference was smaller among elderly patients compared to younger patients (7.2% vs. 11.2%, Figure 2). No significant interactions were observed between SAH and all other variables captured in this study in terms of in-hospital mortality or routine discharge (all p > 0.05).

4. Discussion

In this retrospective analysis of a real-world nationwide database of hospitalizations of the United States, we found that (1) the incidence of SAH among EVT-treated patients was 6.2%, consistent with prior clinical trial data [31], (2) SAH was significantly associated with increased risk of in-hospital mortality and decreased likelihood of good hospitalization outcomes, (3) EVT for DMVOs was associated with a higher risk of SAH, and SAHs associated with DMVO EVTs appeared to carry a particularly elevated mortality risk. Overall, these findings highlight the clinical importance of post-EVT SAHs, particularly for DMVO strokes.
SAH is a known complication of stroke EVT; however, its clinical relevance is not well understood. In addition to the possible extension of post-stroke intraparenchymal hemorrhage into the subarachnoid space, additional factors can contribute to EVT-associated SAH, including endothelial damage during clot retrieval, catheter manipulation, or vessel wall perforation [36]. Unlike intraparenchymal hemorrhagic transformations following ischemic strokes, post-stroke and EVT SAH does not have a universally adopted grading system, and the clinical impact of SAH can vary greatly. While some prior reports have suggested that SAH may be associated with worse outcomes [31,34], others have presented the contrary, suggesting that EVT-associated SAH may be largely clinically benign [35,36,37]. These discrepancies may have stemmed from the small number of patients who experience post-EVT SAH. In this large-scale analysis of 99,219 patients from a real-world dataset, results suggest that SAH is likely associated with net clinical harm. This finding calls for future efforts to better characterize post-EVT SAHs, and to investigate optimal strategies to prevent and manage this poorly understood phenomenon.
Our study also revealed that EVT for DMVO is particularly prone to post-procedure SAH, which corroborates numerous prior reports [26,28,31]. Our study also reports a novel finding that SAHs associated with DMVO EVTs may be more harmful than other EVT-related SAHs in terms of mortality risk. The reasons underlying these findings may be two-fold. First, DMVO strokes are clinically milder. With a smaller treatment target (relief of a milder neurological deficit), patient outcomes may be more sensitive to procedural risks. Second, currently available EVT devices are generally designed for use in large vessels and not optimized for DMVOs, which may have increased the odds of procedural harm [41]. Together, these findings call for careful cost–benefit analyses when considering EVT for DMVO strokes, as well as new thrombectomy devices more tailored for DMVO use. Our study also found that sex and age may modulate the clinical harm of SAH; future work is needed to further explore whether women and elderly patients may warrant additional consideration during EVT decision making and peri-procedural care [16,42].
Our study has several limitations. First, this was a retrospective analysis of an administrative database, and many relevant clinical variables are not available, such as degree of revascularization, grading of intraparenchymal hemorrhagic transformations, proceduralist experience, patient selection protocols, and hospital EVT volume. As such, our study results may have been confounded by these variables that were not available to us. Second, our study outcomes were limited to discharge destinations, and neurological outcomes are available in the database. However, routine discharge is a widely reported and validated surrogate marker for excellent neurological outcomes [26,40], and discharge to home is also a commonly used endpoint [43,44]. Thus, our findings likely remain robust in detecting short-term outcomes as well as hospital death. Third, while we were able to identify posterior and anterior circulation artery occlusions as DMVO, the NRD does not report the location of occlusions within the middle cerebral artery tree. Thus, whether results in our study regarding DMVOs apply to distal MCA (e.g., M3 or M4) occlusions requires confirmation with future studies. Finally, the method with which SAHs were diagnosed was not reported. Although the overall rate of SAH reported in our study (6.2%) is consistent with prior EVT trial data, it is possible that there is under-ascertainment of SAH in real-world practice.

5. Conclusions

SAH is an uncommon but likely clinically detrimental complication following EVT. DMVO, coagulopathy, angioplasty or stenting, concurrent IPH, and female sex were independently associated with higher odds of post-EVT SAH, and SAH associated with DMVO-EVT appeared particularly harmful.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics14171856/s1. Table S1: ICD-10 codes used for this study, Table S2: Other comorbidities

Author Contributions

Conceptualization, H.C., M.C. and D.G.; methodology, H.C. and M.K.; software, H.C. and M.K.; formal analysis, M.C.; resources, D.G.; data curation, H.C.; writing—original draft preparation, H.C. and M.C.; writing—review and editing, A.M. and D.G.; visualization, H.C.; supervision, D.G.; project administration, D.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no funding.

Institutional Review Board Statement

Patient identifiers are not part of the NRD, so this study was exempt from institutional review board approval or informed consent.

Informed Consent Statement

Not applicable.

Data Availability Statement

Restrictions apply to the availability of these data. Data were obtained from the Healthcare Cost and Utilization Project (HCUP) and are available for purchase at https://hcup-us.ahrq.gov with the permission of HCUP.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.; Demaerschalk, B.M.; Hoh, B.; et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2019, 50, e344–e418. [Google Scholar] [PubMed]
  2. Turc, G.; Bhogal, P.; Fischer, U.; Khatri, P.; Lobotesis, K.; Mazighi, M.; Schellinger, P.D.; Toni, D.; de Vries, J.; White, P.; et al. European Stroke Organisation (ESO)—European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke. J. Neurointerv. Surg. 2023, 15, e8. [Google Scholar] [CrossRef] [PubMed]
  3. Charbonnier, G.; Bonnet, L.; Biondi, A.; Moulin, T. Intracranial Bleeding after Reperfusion Therapy in Acute Ischemic Stroke. Front. Neurol. 2021, 11, 629920. [Google Scholar] [CrossRef]
  4. Costalat, V.; Jovin, T.G.; Albucher, J.F.; Cognard, C.; Henon, H.; Nouri, N.; Gory, B.; Richard, S.; Marnat, G.; Sibon, I.; et al. Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size. N. Engl. J. Med. 2024, 390, 1677–1689. [Google Scholar] [CrossRef]
  5. Yoshimura, S.; Sakai, N.; Yamagami, H.; Uchida, K.; Beppu, M.; Toyoda, K.; Matsumaru, Y.; Matsumoto, Y.; Kimura, K.; Takeuchi, M.; et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N. Engl. J. Med. 2022, 386, 1303–1313. [Google Scholar] [CrossRef]
  6. Sarraj, A.; Hassan, A.E.; Abraham, M.G.; Ortega-Gutierrez, S.; Kasner, S.E.; Hussain, M.S.; Chen, M.; Blackburn, S.; Sitton, C.W.; Churilov, L.; et al. Trial of Endovascular Thrombectomy for Large Ischemic Strokes. N. Engl. J. Med. 2023, 388, 1259–1271. [Google Scholar] [CrossRef]
  7. Huo, X.; Ma, G.; Tong, X.; Zhang, X.; Pan, Y.; Nguyen, T.N.; Yuan, G.; Han, H.; Chen, W.; Wei, M.; et al. Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. N. Engl. J. Med. 2023, 388, 1272–1283. [Google Scholar] [CrossRef] [PubMed]
  8. Bendszus, M.; Fiehler, J.; Subtil, F.; Bonekamp, S.; Aamodt, A.H.; Fuentes, B.; Gizewski, E.R.; Hill, M.D.; Krajina, A.; Pierot, L.; et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: Multicentre, open-label, randomised trial. Lancet 2023, 402, 1753–1763. [Google Scholar] [CrossRef] [PubMed]
  9. Chen, H.; Colasurdo, M. Endovascular thrombectomy for large ischemic strokes: Meta-analysis of six multicenter randomized controlled trials. J. Neurointerv. Surg. 2024. [Google Scholar] [CrossRef]
  10. Chen, H.; Lee, J.S.; Michel, P.; Yan, B.; Chaturvedi, S. Endovascular Stroke Thrombectomy for Patients with Large Ischemic Core. JAMA Neurol. 2024. [Google Scholar] [CrossRef]
  11. Saber, H.; Hinman, J.; Mun, K.; Kaneko, N.; Szeder, V.; Tateshima, S.; Nour, M.; Raychev, R.; Ooi, Y.C.; Jahan, R.; et al. Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with Dementia. Stroke Vasc. Interv. Neurol. 2022, 2, e000164. [Google Scholar] [CrossRef]
  12. Salwi, S.; Cutting, S.; Salgado, A.D.; Espaillat, K.; Fusco, M.R.; Froehler, M.T.; Chitale, R.V.; Kirshner, H.; Schrag, M.; Jasne, A.; et al. Mechanical Thrombectomy in Patients with Ischemic Stroke with Prestroke Disability. Stroke 2020, 51, 1539–1545. [Google Scholar] [CrossRef] [PubMed]
  13. Aloizou, A.-M.; Richter, D.; Charles James, J.; Lukas, C.; Gold, R.; Krogias, C. Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with Malignancy: A Systematic Review. J. Clin. Med. 2022, 11, 4696. [Google Scholar] [CrossRef] [PubMed]
  14. Regenhardt, R.W.; Young, M.J.; Etherton, M.R.; Das, A.S.; Stapleton, C.J.; Patel, A.B.; Lev, M.H.; Hirsch, J.A.; Rost, N.S.; Leslie-Mazwi, T.M. Toward a more inclusive paradigm: Thrombectomy for stroke patients with pre-existing disabilities. J. Neurointerv. Surg. 2021, 13, 865–868. [Google Scholar] [CrossRef] [PubMed]
  15. Al-Mufti, F.; Schirmer, C.M.; Starke, R.M.; Chaudhary, N.; De Leacy, R.; Tjoumakaris, S.I.; Haranhalli, N.; Abecassis, I.J.; Amuluru, K.; Bulsara, K.R.; et al. Thrombectomy in special populations: Report of the Society of NeuroInterventional Surgery Standards and Guidelines Committee. J. Neurointerv. Surg. 2022, 14, 1033–1041. [Google Scholar] [CrossRef]
  16. Chen, H.; Jindal, G.; Miller, T.R.; Gandhi, D.; Chaturvedi, S. Stroke Thrombectomy in the Elderly: Efficacy, Safety, and Special Considerations. Stroke Vasc. Interv. Neurol. 2023, 3, e000634. [Google Scholar] [CrossRef]
  17. Desai, S.M.; Haussen, D.C.; Aghaebrahim, A.; Al-Bayati, A.R.; Santos, R.; Nogueira, R.G.; Jovin, T.G.; Jadhav, A.P. Thrombectomy 24 hours after stroke: Beyond DAWN. J. Neurointerv. Surg. 2018, 10, 1039–1042. [Google Scholar] [CrossRef]
  18. Rodriguez-Calienes, A.; Galecio-Castillo, M.; Vivanco-Suarez, J.; Mohamed, G.A.; Toth, G.; Sarraj, A.; Pujara, D.; Chowdhury, A.A.; Farooqui, M.; Ghannam, M.; et al. Endovascular thrombectomy beyond 24 hours from last known well: A systematic review with meta-analysis. J. Neurointerv. Surg. 2024, 16, 670–676. [Google Scholar] [CrossRef]
  19. Kobeissi, H.; Ghozy, S.; Adusumilli, G.; Kadirvel, R.; Brinjikji, W.; Rabinstein, A.A.; Kallmes, D.F. Endovascular Therapy for Stroke Presenting beyond 24 Hours. JAMA Netw. Open 2023, 6, e2311768. [Google Scholar] [CrossRef]
  20. Nogueira, R.G.; Doheim, M.F.; Al-Bayati, A.R.; Lee, J.S.; Haussen, D.C.; Mohammaden, M.; Lang, M.; Starr, M.; Rocha, M.; da Câmara, C.P.; et al. Distal Medium Vessel Occlusion Strokes: Understanding the Present and Paving the Way for a Better Future. J. Stroke 2024, 26, 190–202. [Google Scholar] [CrossRef]
  21. Ospel, J.M.; Nguyen, T.N.; Jadhav, A.P.; Psychogios, M.-N.; Clarençon, F.; Yan, B.; Goyal, M. Endovascular Treatment of Medium Vessel Occlusion Stroke. Stroke 2024, 55, 769–778. [Google Scholar] [CrossRef] [PubMed]
  22. Meyer, L.; Stracke, C.P.; Jungi, N.; Wallocha, M.; Broocks, G.; Sporns, P.B.; Maegerlein, C.; Dorn, F.; Zimmermann, H.; Naziri, W.; et al. Thrombectomy for Primary Distal Posterior Cerebral Artery Occlusion Stroke. JAMA Neurol. 2021, 78, 434–444. [Google Scholar] [CrossRef] [PubMed]
  23. Nguyen, T.N.; Qureshi, M.M.; Strambo, D.; Strbian, D.; Räty, S.; Herweh, C.; Abdalkader, M.; Olive-Gadea, M.; Ribo, M.; Psychogios, M.; et al. Endovascular Versus Medical Management of Posterior Cerebral Artery Occlusion Stroke: The PLATO Study. Stroke 2023, 54, 1708–1717. [Google Scholar] [CrossRef]
  24. Sabben, C.; Charbonneau, F.; Delvoye, F.; Strambo, D.; Heldner, M.R.; Ong, E.; Ter Schiphorst, A.; Henon, H.; Ben Hassen, W.; Agasse-Lafont, T.; et al. Endovascular Therapy or Medical Management Alone for Isolated Posterior Cerebral Artery Occlusion: A Multicenter Study. Stroke 2023, 54, 928–937. [Google Scholar] [CrossRef]
  25. Maulucci, F.; Disanto, G.; Bianco, G.; Pileggi, M.; Fischer, U.; Padlina, G.; Strambo, D.; Michel, P.; Kahles, T.; Nedeltchev, K.; et al. Endovascular therapy outcome in isolated posterior cerebral artery occlusion strokes: A multicenter analysis of the Swiss Stroke Registry. Eur. Stroke J. 2023, 8, 575–580. [Google Scholar] [CrossRef]
  26. Chen, H.; Khunte, M.; Colasurdo, M.; Malhotra, A.; Gandhi, D. Thrombectomy vs. Medical Management for Posterior Cerebral Artery Stroke: Systematic Review, Meta-Analysis, and Real-World Data. Neurology 2024, 102, e209315. [Google Scholar] [CrossRef] [PubMed]
  27. Goyal, M.; Cimflova, P.; Ospel, J.M.; Chapot, R. Endovascular treatment of anterior cerebral artery occlusions. J. Neurointerv. Surg. 2021, 13, 1007–1011. [Google Scholar] [CrossRef]
  28. Chen, H.; Khunte, M.; Malhotra, A.; Gandhi, D.; Colasurdo, M. Endovascular thrombectomy versus medical management for moderate-to-severe anterior cerebral artery occlusion stroke. J. Neurol. 2024. [Google Scholar] [CrossRef] [PubMed]
  29. Meyer, L.; Stracke, P.; Broocks, G.; Elsharkawy, M.; Sporns, P.; Piechowiak, E.I.; Kaesmacher, J.; Maegerlein, C.; Hernandez Petzsche, M.R.; Zimmermann, H.; et al. Thrombectomy versus Medical Management for Isolated Anterior Cerebral Artery Stroke: An International Multicenter Registry Study. Radiology 2023, 307, e220229. [Google Scholar] [CrossRef]
  30. Salim, H.A.; Yedavalli, V.; Musmar, B.; Adeeb, N.; Naamani, K.E.L.; Henninger, N.; Sundararajan, S.H.; Kühn, A.L.; Khalife, J.; Ghozy, S.; et al. Endovascular therapy versus best medical management in distal medium middle cerebral artery acute ischaemic stroke: A multinational multicentre propensity score-matched study. J. Neurol. Neurosurg. Psychiatry 2024. [Google Scholar] [CrossRef]
  31. Lee, H.; Qureshi, A.M.; Mueller-Kronast, N.H.; Zaidat, O.O.; Froehler, M.T.; Liebeskind, D.S.; Pereira, V.M. Subarachnoid Hemorrhage in Mechanical Thrombectomy for Acute Ischemic Stroke: Analysis of the STRATIS Registry, Systematic Review, and Meta-Analysis. Front. Neurol. 2021, 12, 663058. [Google Scholar] [CrossRef] [PubMed]
  32. Tarkiainen, J.; Hovi, V.; Pyysalo, L.; Ronkainen, A.; Frösen, J. The clinical course and outcomes of non-aneurysmal subarachnoid hemorrhages in a single-center retrospective study. Acta Neurochir. 2023, 165, 2843–2853. [Google Scholar] [CrossRef]
  33. Zöllner, J.P.; Konczalla, J.; Stein, M.; Roth, C.; Krakow, K.; Kaps, M.; Steinmetz, H.; Rosenow, F.; Misselwitz, B.; Strzelczyk, A. Acute symptomatic seizures in intracerebral and subarachnoid hemorrhage: A population study of 19,331 patients. Epilepsy Res. 2020, 161, 106286. [Google Scholar] [CrossRef] [PubMed]
  34. van Landeghem, N.; Ziegenfuß, C.; Demircioglu, A.; Dammann, P.; Jabbarli, R.; Haubold, J.; Forsting, M.; Wanke, I.; Köhrmann, M.; Frank, B.; et al. Impact of post-thrombectomy isolated subarachnoid hemorrhage on neurological outcomes in patients with anterior ischemic stroke—A retrospective single-center observational study. Neuroradiology 2024. [Google Scholar] [CrossRef] [PubMed]
  35. Kim, D.Y.; Baik, S.H.; Jung, C.; Kim, J.Y.; Han, S.-G.; Kim, B.J.; Kang, J.; Bae, H.-J.; Kim, J.H. Predictors and Impact of Sulcal SAH after Mechanical Thrombectomy in Patients with Isolated M2 Occlusion. Am. J. Neuroradiol. 2022, 43, 1292–1298. [Google Scholar] [CrossRef] [PubMed]
  36. Benalia, V.H.; Aghaebrahim, A.; Cortez, G.M.; Sauvageau, E.; Hanel, R.A. Evaluation of pure subarachnoid hemorrhage after mechanical thrombectomy in a series of 781 consecutive patients. Interv. Neuroradiol. 2023. [Google Scholar] [CrossRef]
  37. Yoon, W.; Jung, M.Y.; Jung, S.H.; Park, M.S.; Kim, J.T.; Kang, H.K. Subarachnoid Hemorrhage in a Multimodal Approach Heavily Weighted toward Mechanical Thrombectomy with Solitaire Stent in Acute Stroke. Stroke 2013, 44, 414–419. [Google Scholar] [CrossRef]
  38. Deb-Chatterji, M.; Pinnschmidt, H.; Flottmann, F.; Leischner, H.; Alegiani, A.; Brekenfeld, C.; Fiehler, J.; Gerloff, C.; Thomalla, G. Stroke patients treated by thrombectomy in real life differ from cohorts of the clinical trials: A prospective observational study. BMC Neurol. 2020, 20, 81. [Google Scholar] [CrossRef]
  39. Quan, H.; Sundararajan, V.; Halfon, P.; Fong, A.; Burnand, B.; Luthi, J.-C.; Saunders, L.D.; Beck, C.A.; Feasby, T.E.; Ghali, W.A. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data. Med. Care 2005, 43, 1130–1139. [Google Scholar] [CrossRef]
  40. Dicpinigaitis, A.J.; Dick-Godfrey, R.; Gellerson, O.; Shapiro, S.D.; Kamal, H.; Ghozy, S.; Kaur, G.; Desai, S.M.; Ortega-Gutierrez, S.; Yaghi, S.; et al. Real-World Outcomes of Endovascular Thrombectomy for Basilar Artery Occlusion: Results of the BArONISStudy. Ann. Neurol. 2023, 94, 55–60. [Google Scholar] [CrossRef]
  41. Dmytriw, A.A.; Musmar, B.; Salim, H.; Ghozy, S.; Siegler, J.E.; Kobeissi, H.; Shaikh, H.; Khalife, J.; Abdalkader, M.; Klein, P.; et al. Incidence and clinical outcomes of perforations during mechanical thrombectomy for medium vessel occlusion in acute ischemic stroke: A retrospective, multicenter, and multinational study. Eur. Stroke J. 2024, 9, 328–337. [Google Scholar] [CrossRef] [PubMed]
  42. Dmytriw, A.A.; Ku, J.C.; Yang, V.X.D.; Hui, N.; Uchida, K.; Morimoto, T.; Spears, J.; Marotta, T.R.; Diestro, J.D.B. Do Outcomes between Women and Men Differ after Endovascular Thrombectomy? A Meta-analysis. AJNR Am. J. Neuroradiol. 2021, 42, 910–915. [Google Scholar] [CrossRef] [PubMed]
  43. Chen, H.; Khunte, M.; Colasurdo, M.; Malhotra, A.; Gandhi, D. Intravenous thrombolysis prior to endovascular thrombectomy in elderly stroke patients: An analysis of the National Inpatient Sample database. J. Neurol. Sci. 2023, 454, 120842. [Google Scholar] [CrossRef] [PubMed]
  44. Chen, H.; Khunte, M.; Colasurdo, M.; Jindal, G.; Malhotra, A.; Gandhi, D.; Chaturvedi, S. Associations of Osteoarthritis With Thrombectomy Utilization and Outcomes for Large Vessel Acute Ischemic Stroke. Stroke 2023, 54, 518–526. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 14 01856 g001
Figure 1. Hospitalization outcomes of patients with or without subarachnoid hemorrhage following endovascular thrombectomy for acute ischemic stroke. Routine discharge was defined as discharge to home to self-care. Multivariable adjustments were made for patient age, sex, site of vascular occlusion, stroke severity, stroke risk factors, antithrombotic medication use, and medical comorbidities. p-values less than 0.05 were deemed statistically significant.
Figure 1. Hospitalization outcomes of patients with or without subarachnoid hemorrhage following endovascular thrombectomy for acute ischemic stroke. Routine discharge was defined as discharge to home to self-care. Multivariable adjustments were made for patient age, sex, site of vascular occlusion, stroke severity, stroke risk factors, antithrombotic medication use, and medical comorbidities. p-values less than 0.05 were deemed statistically significant.
Diagnostics 14 01856 g001
Diagnostics 14 01856 g002
Figure 2. Hospitalization outcomes of patients with or without subarachnoid hemorrhage following endovascular thrombectomy for acute ischemic stroke stratified by patient subgroups. Adjusted odds ratios (aOR) accounted for patient age, sex, site of vascular occlusion, stroke severity, stroke risk factors, antithrombotic medication use, and medical comorbidities. p-values less than 0.05 were deemed statistically significant.
Figure 2. Hospitalization outcomes of patients with or without subarachnoid hemorrhage following endovascular thrombectomy for acute ischemic stroke stratified by patient subgroups. Adjusted odds ratios (aOR) accounted for patient age, sex, site of vascular occlusion, stroke severity, stroke risk factors, antithrombotic medication use, and medical comorbidities. p-values less than 0.05 were deemed statistically significant.
Diagnostics 14 01856 g002
Table 1. Patient characteristics.
Table 1. Patient characteristics.
Total CohortNo SAHSAH
Characteristic—% (n) or Mean (SD)N = 99,219 (100%)N = 93,045 (93.8%)N = 6174 (6.2%)SMD
Female sex51.1% (50,657)50.7% (47,191)56.1% (3466)0.109
Age (years)69.1 (14.8)69.1 (14.8)69.6 (14.4)0.032
NIH Stroke Scale15.0 (7.8)15.0 (7.8)15.1 (7.9)0.018
Posterior circulation7.6% (7551)7.8% (7295)4.2% (257)0.185
Site of occlusion
  Large vessel (ICA, BA, VA)11.7% (11,619)12.0% (11,119)8.1% (500)0.141
  Middle cerebral artery (M1, M2, M3 etc.)85.8% (85,167)85.6% (79,616)89.9% (5552)0.145
  Distal/medium vessel (ACA, PCA)2.5% (2433)2.5% (2311)2.0% (122)0.037
Non-embolic etiology62.3% (61,822)62.3% (57,993)62.0% (3829)0.006
Bleeding risk factors
  Intravenous tPA use33.9% (33,666)33.9% (31,566)34.0% (2100)0.002
  Anticoagulant use17.7% (17,580)17.8% (16,562)16.5% (1018)0.035
  Antiplatelet use27.1% (26,930)27.2% (25,338)25.8% (1592)0.033
  Coagulopathy10.4% (10,358)10.1% (9426)15.1% (932)0.139
Stroke risk factors
  Atrial fibrillation or flutter41.3% (41,008)41.3% (38,468)41.1% (2540)0.004
  Hypertension82.5% (81,820)82.6% (76,817)81.0% (5002)0.039
  Smoking history18.4% (18,258)18.5% (17,251)16.3% (1006)0.061
  Hyperlipidemia58.7% (58,284)58.9% (54,786)56.7% (3498)0.045
  Diabetes11.9% (11,815)12.0% (11,151)10.7% (663)0.040
  Diabetes (complicated)17.5% (17,404)17.5% (16,288)18.1% (1117)0.015
  Chronic heart failure26.8% (26,570)26.7% (24,853)27.8% (1716)0.024
Angioplasty or stenting10.3% (10,180)10.1% (9404)12.6% (776)0.074
Concurrent intraparenchymal hemorrhage17.5% (17,366)17.2% (15,958)22.8% (1408)0.135
Table 2. Predictors of SAH risk.
Table 2. Predictors of SAH risk.
PredictorAdjusted OR [95%CI]p-Value
Higher risk
  DMVO *1.50 [1.07–2.09]0.017
  Coagulopathy1.47 [1.33–1.62]<0.001
  Angioplasty1.44 [1.22–1.70]<0.001
  Concurrent intraparenchymal hemorrhage1.39 [1.26–1.55]<0.001
  MCA *1.28 [1.08–1.52]0.004
  Female sex1.27 [1.17–1.37]<0.001
No change in risk
  tPA1.03 [0.94–1.12]0.55
  Non-embolic etiology1.02 [0.94–1.10]0.65
  Age1.01 [0.98–1.05]0.46
  NIHSS0.99 [0.93–1.05]0.68
  Antiplatelet use0.98 [0.91–1.05]0.54
Lower risk
  Anticoagulant use0.89 [0.80–1.00]0.041
  Posterior cirrculation0.61 [0.48–0.77]<0.001
*: Compared to ICA or VB.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chen, H.; Colasurdo, M.; Khunte, M.; Malhotra, A.; Gandhi, D. Post-Thrombectomy Subarachnoid Hemorrhage: Incidence, Predictors, Clinical Relevance, and Effect Modulators. Diagnostics 2024, 14, 1856. https://doi.org/10.3390/diagnostics14171856

AMA Style

Chen H, Colasurdo M, Khunte M, Malhotra A, Gandhi D. Post-Thrombectomy Subarachnoid Hemorrhage: Incidence, Predictors, Clinical Relevance, and Effect Modulators. Diagnostics. 2024; 14(17):1856. https://doi.org/10.3390/diagnostics14171856

Chicago/Turabian Style

Chen, Huanwen, Marco Colasurdo, Mihir Khunte, Ajay Malhotra, and Dheeraj Gandhi. 2024. "Post-Thrombectomy Subarachnoid Hemorrhage: Incidence, Predictors, Clinical Relevance, and Effect Modulators" Diagnostics 14, no. 17: 1856. https://doi.org/10.3390/diagnostics14171856

APA Style

Chen, H., Colasurdo, M., Khunte, M., Malhotra, A., & Gandhi, D. (2024). Post-Thrombectomy Subarachnoid Hemorrhage: Incidence, Predictors, Clinical Relevance, and Effect Modulators. Diagnostics, 14(17), 1856. https://doi.org/10.3390/diagnostics14171856

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop